Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.25
Bid: 5.00
Ask: 5.50
Change: 0.00 (0.00%)
Spread: 0.50 (10.00%)
Open: 5.24
High: 5.50
Low: 5.24
Prev. Close: 5.25
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of Placing

17 Nov 2015 12:51

RNS Number : 0191G
Allergy Therapeutics PLC
17 November 2015
 



17 November 2015

 

Allergy Therapeutics plc

("Allergy Therapeutics", the "Company" or the "Group")

 

Results of Placing

 

Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, is pleased to announce the successful completion of the Placing announced earlier today.

 

A total of 41,005,500 new ordinary shares (the "New Shares") have been placed by Panmure Gordon at a price of 28 pence per share (the "Placing Price") to raise approximately £11.5 million (before expenses) for the Company. The New Shares being issued represent approximately 7.5 per cent. of the issued ordinary share capital of the Company prior to the Placing. The Placing Price represents a discount of 0.6 per cent. to the average mid-market closing price over the previous 60 trading days up to and including 16 November 2015, being the last practicable day before the announcement of the Placing.

 

Manuel Llobet, Chief Executive Officer, stated:

"We are delighted with the result of this oversubscribed fundraising and would like to take the opportunity to welcome new investors in the Company as well as thank our existing investors for their continued support. We look forward to putting the proceeds of the Placing to use in the business, with a view to generating significant additional value for our shareholders".

 

Panmure Gordon is acting as Financial Adviser, Nominated Adviser and Corporate Broker in respect of the Placing. Unless the context requires otherwise, capitalised terms in this announcement have the same meanings as defined in the Company's announcement released via RNS at 7.01am today.

 

Related Party Transaction

 

Where a company enters into a related party transaction, under the AIM Rules for Companies, the independent directors of the company are required, after consulting with the company's nominated adviser, to state whether, in their opinion, the transaction is fair and reasonable in so far as its shareholders are concerned.

 

As at the date of this announcement, Beagle Partners LLP ("Beagle Partners") has an interest in 125,183,783 Ordinary Shares (on behalf of Southern Fox Investments Limited as its investment manager), representing 22.9 per cent. of the issued share capital of the Company. Beagle Partners has subscribed £0.5 million for 1,785,000 Ordinary Shares in the Placing. The issue of Ordinary Shares to Beagle Partners constitutes a related party transaction under Rule 13 of the AIM Rules for Companies.

 

The Directors, having consulted with Panmure Gordon, the Company's nominated adviser, consider that the terms of Beagle Partners' participation in the Placing are fair and reasonable insofar as the shareholders are concerned.

 

Application for admission to trading on AIM and total voting rights

 

Application has been made to the London Stock Exchange for admission to trading of the New Shares on AIM ("Admission"). It is expected that Admission will take place at 8:00 a.m. on 20 November 2015 (at which time the Placing will become unconditional) and that dealings in the New Shares on AIM will commence at the same time.

 

The New Shares will, when issued, be credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares in the capital of the Company, including the right to receive all dividends or other distributions made, paid or declared in respect of such shares after the date of issue of the New Shares.

 

Allergy Therapeutics' enlarged issued ordinary share capital immediately following Admission will be 586,853,419 Ordinary Shares with voting rights attached. The Company has no shares in Treasury; therefore the total number of voting rights in Allergy Therapeutics is 586,853,419. This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

 

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Ian Postlethwaite

Panmure Gordon

+44 (0) 207 886 2500

Freddy Crossley / Peter Steel / Duncan Monteith, Corporate Finance

Tom Salvesen, Corporate Broking

FTI Consulting

+44 (0) 203 727 1000

Simon Conway / Victoria Foster Mitchell

 

www.allergytherapeutics.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGGGBCGUPAGPM
Date   Source Headline
26th Jul 201010:06 amRNSHolding(s) in Company
22nd Jul 201012:24 pmRNSTrading Statement
19th Jul 201012:58 pmRNSHolding(s) in Company
1st Jul 201010:04 amRNSAcquisition
31st Mar 20107:00 amRNSTotal Voting Rights
26th Mar 20109:14 amRNSHolding(s) in Company
24th Mar 20109:02 amRNSDirector/PDMR Shareholding
11th Mar 20102:14 pmRNSHolding(s) in Company
1st Mar 20107:00 amRNSInterim Results
20th Jan 20108:46 amRNSNotification of Interim Results and Trading update
19th Nov 200911:23 amRNSAGM Result
16th Nov 200912:34 pmRNSAnnual General Meeting and Nominations Committee
30th Oct 20097:00 amRNSTotal Voting Rights
19th Oct 20098:51 amRNSAvailability of Annual Report
16th Oct 20099:39 amRNSGrant of Options
14th Oct 200911:00 amRNSDirector/PDMR Shareholding
1st Oct 20098:58 amRNSDirector/PDMR Shareholding
25th Sep 20094:42 pmRNSExercise of Warrants
21st Sep 20097:00 amRNSFinal Results
30th Jul 20097:00 amRNSTotal Voting Rights
23rd Jul 20097:00 amRNSEuropean Patent Granted
17th Jul 20098:44 amRNSProvisional Grant of Options
10th Jul 20098:06 amRNSDirectors Holdings
10th Jul 20098:05 amRNSHolding(s) in Company
9th Jul 20097:00 amRNSPatent Granted in Japan
8th Jul 20092:33 pmRNSDirector/PDMR Shareholding
6th Jul 20091:31 pmRNSExercise of Warrants
3rd Jul 20094:26 pmRNSHolding(s) in Company
3rd Jul 20093:39 pmRNSHolding(s) in Company
3rd Jul 200911:36 amRNSHolding(s) in Company
3rd Jul 200911:29 amRNSHolding(s) in Company
2nd Jul 200912:27 pmRNSHolding(s) in Company
1st Jul 20094:28 pmRNSHolding(s) in Company
1st Jul 20098:01 amRNSTotal Voting Rights
30th Jun 200912:00 pmRNSAGM Result
29th Jun 20095:33 pmRNSTotal Voting Rights
29th Jun 20094:34 pmRNSResult of Offer to Qualifying Participants
22nd Jun 200910:35 amRNSAdmission of New Shares
12th Jun 20099:56 amRNSDirector/PDMR Shareholding
12th Jun 20097:00 amRNSFundraising
8th Apr 20097:00 amRNSDistribution agreement with Nycomed
7th Apr 20092:38 pmRNSHolding(s) in Company
1st Apr 20092:28 pmRNSHolding(s) in Company
31st Mar 20097:00 amRNSHalf Yearly Report
27th Mar 200910:13 amRNSNotice of Results
20th Mar 200911:15 amRNSRenegotiation of Debt Facilities - Replacement
20th Mar 200910:44 amRNSRenegotiation of Debt Facilities
4th Mar 20097:00 amRNSGrass EU Submission
11th Dec 20083:24 pmRNSHolding(s) in Company
20th Nov 200811:52 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.